Rosebud Biosciences Analysis
What is Rosebud Biosciences?
Rosebud Biosciences develops therapies for rare genetic diseases in children using organoids that model human development and replicate genetic mutations.
Employees
3
Founded
2020
Product Features & Capabilities
- Organoid platform, targeted therapies for rare genetic diseases, cardiac organoids, hepatic organoids, neural organoids, kidney organoids, drug screening using human induced pluripotent stem cells (hiPSCs), mutation-specific organoid models.
Who are the founders of Rosebud Biosciences
KW
Kitch Wilson
CEO
EL
Evan Lyall
CTO
Business Model
Collaborates with pharma for drug development; funding through grants and investments.
Market Focus
Rosebud Biosciences primarily focuses on the biotechnology industry, specifically developing therapies for rare genetic diseases in children using organoid technology to model human development and replicate genetic mutations.
Investors
- Y Combinator
- National Science Foundation (NSF)
- 10X Capital
- Arvantis Group
- Gaingels
Competitors Overview
Rosebud Biosciences operates in the biotechnology sector, focusing on developing therapies for rare genetic diseases using organoids that replicate genetic mutations. Its main competitors include:
- Gameto: Specializes in female reproductive longevity and cellular reprogramming, which is a dif
See something that needs updating? Suggest edits to this profile.